L ow-density lipoprotein (LDL) is a complex particle that comprises triglycerides and cholesteryl ester molecules in its core; unesterified cholesterol molecules, of which approximately one third lie in the core and two thirds reside on the surface; a surface monolayer of phospholipid molecules; and a single copy of apolipoprotein B100 (ApoB100) (4536 amino acids). 1
Clinical Perspective on p 2443
Retention of LDL in the subendothelial space of arteries is a hallmark of the initial pathogenesis of atherosclerosis. 2 Subsequently, the trapped LDL particles undergo various biochemical modifications that are mediated by oxidative, lipolytic, and proteolytic enzymes and reactive oxygen species. [3] [4] [5] Clinical and laboratory data have shown that modified LDL instigates chronic inflammatory responses in the artery wall, indicating that the modifications confer LDL with bioactivities that effect initiation, progression, and complications of atherosclerosis. 6 For instance, modified phospholipids of LDL, such as lysophosphatidylcholine and 1-palmitoyl-2-(5Ј-oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC), can stimulate endothelial cells, smooth muscle cells, and macrophages. 7, 8 It is known now that such atherogenic lipids initiate innate immune response through activation of Toll-like receptors. 9 -11 Collectively, these data imply that modification of LDL generates endogenous ligands that trigger activation of the innate immune system that promotes atherosclerosis.
Although the hypothesis that modification of LDL plays a major role in the pathogenesis of atherosclerosis is well established, recent reports have shown that native peptides of ApoB100 trigger activation of adaptive immune responses. [12] [13] [14] Using a library of malondialdehyde-modified or native polypeptides that encompassed the entire sequence of ApoB100, Fredrikson et al 15 recently identified Ͼ100 native peptides of ApoB100 that could be recognized by circulating IgM or IgG autoantibodies from atherosclerotic patients. Subsequent work demonstrated that such native epitopes exist in carotid plaque, with nearly 3-fold higher levels in plaques from individuals with clinical symptoms than in asymptomatic individuals. 16 To enhance our current understanding of the biological activities of LDL in atherosclerosis, we determined whether sequences of ApoB100 activate monocytes/macrophages. By screening a peptide library of ApoB100, we identified a peptide that had sequence-specific bioactivity, inducing inflammatory responses in innate immune cells and ex vivo cultured carotid plaques by initiating mitogen-activated protein kinase (MAPK) and Ca 2ϩ -dependent signaling pathways. We have named this novel peptide ApoB100 dangerassociated signal 1 (ApoBDS-1).
Methods
For an expanded Methods section, please refer to the online-only Data Supplement.
Screen of the ApoB100 Library
The screen for potential peptides was performed with the use of the monocytic cell line THP-1 (TIB-202; ATCC, VA). Cells were cultured in RPMI-1640 medium (Gibco Invitrogen, Carlsbad, CA) that was supplemented with 10% (vol/vol) fetal calf serum (Sigma-Aldrich, St Louis, MO), penicillin (100 U/mL)/streptomycin (100 g/mL) (Sigma-Aldrich), 2 mmol/L L-glutamine (Gibco Invitrogen), 15 mmol/L HEPES (Gibco Invitrogen), and 11 mmol/L sodium bicarbonate (Sigma-Aldrich) and maintained in a humidified atmosphere of 5% CO 2 at 37°C. For the experiments, 2.5ϫ10 5 cells per well were incubated in duplicate with each of native ApoB100 peptides.
Ex Vivo Stimulation of Atherosclerotic Plaque Tissue
Eight carotid artery plaques were collected from patients who were undergoing endarterectomy at Karolinska University Hospital. Informed consent was obtained from all subjects. The investigation was approved by the Ethical Committee of Northern Stockholm and was in agreement with institutional guidelines and the principles that have been set forth in the Declaration of Helsinki.
Fresh plaques were processed to remove calcified tissue, cut into small pieces (Ͻ2 mm 3 ), and washed with cold phosphate-buffered saline. The pieces were distributed equally in a 48-well plate (Ϸ0.1 mg per well). Two to 4 hours after incubation in RPMI with 10% fetal calf serum, the tissues were stimulated in duplicate for 24 hours with the indicated concentrations of ApoBDS-1.
Immunofluorescent Detection of ApoBDS-1 in Carotid Atherosclerotic Plaques
For detection of ApoBDS-1, an affinity-purified rabbit IgG anti-ApoBDS-1 antibody was generated (Anaspec, San Jose, CA). The reactivity was verified against a set of ApoB100 peptides, demonstrating high specificity to ApoBDS-1 ( Figure I in the online-only Data Supplement). Immunofluorescent staining for ApoBDS-1 was performed on acetone-fixed frozen sections from 4 carotid endarterectomy plaques with the use of the ApoBDS-1 antibody, followed by DyLight 594 anti-rabbit IgG antibody (Vector Laboratories, Burlingame, CA). Sections from each plaque were costained with monoclonal antibody against human smooth muscle ␣-actin (M0851; Dako, Glostrup, Denmark), monoclonal antibody against human von Willebrand factor (M0616; Dako), or monoclonal antibody against human CD68 (556059; BD Biosciences, Franklin Lakes, NJ). Images were captured with a Leica TCS SP5 confocal microscope (Leica, Wetzlar, Germany).
As a specificity control, ApoBDS-1 peptide (20 g/mL) was applied to the consecutive sections stained with ApoBDS-1 antibody. The specific ApoBDS-1 signals were quantified. In brief, fluorescence per pixel was obtained by the conversion of images to grayscale and a definition of global threshold with the use of Otsu's method. 17 Total number of pixels above the threshold was calculated with the use of Matlab software (MathWorks, MI).
Detection of ApoBDS-1 in Carotid Plaque Homogenates
Plaques were rinsed in cold phosphate-buffered saline and disrupted in cold T-PER tissue protein extraction reagent (Thermo Scientific, MA) supplemented with Halt protease inhibitor cocktail and EDTA (Thermo Scientific) with the use of an Ultraturrax homogenizer (IKA-Labortechnik, Germany). Crude homogenates were centrifuged at 10 000g for 10 minutes, and the supernatant was used for identification of ApoBDS-1. The protein content was determined by Bradford (BioRad, LA).
For Western blot analysis of ApoBDS-1, samples were diluted with Laemmli sample buffer (Bio-Rad), boiled, and loaded in equal concentrations; 0.5g of ApoBDS-1 was included as a positive control. Samples were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane (GE Healthcare, Uppsala, Sweden) with the use of a semidry electrophoretic transfer cell at 125 mA for 45 minutes. ApoBDS-1-containing fragments were detected with the use of the anti-ApoBDS-1 antibody (1.6 g/mL), followed with goat anti-rabbit IgG-horseradish peroxidase (Dako), and visualized with an enhanced chemiluminescence substrate (GE Healthcare).
For the chromatographic analysis, 2 mg of plaque homogenate was fractionated with the use of an HR10/30 Superose 6 column (GE Healthcare) and a Discovery BIO GFC-500 as precolumn (5 cmϫ7.8 ID; Supelco, Sigma-Aldrich) coupled to a Prominence ultrafast liquid chromatography system (Shimadzu, Kyoto, Japan) and equilibrated with ammonium bicarbonate buffer, pH 7.4. Forty-eight fractions of 500 L each were collected on a 96-well enzyme-linked immunosorbent assay plate with a Foxy Jr fraction collector (Teledyne Isco Inc, NE). Molecular weight calibration of the system was performed ( Figure II in the online-only Data Supplement) with the use of high-and low-molecular-weight calibration kits (GE Healthcare). To detect ApoBDS-1, 96-well plates were coated overnight with the collected fractions, blocked with 1% gelatin for 1 hour, and then incubated with anti-ApoBDS-1 (1 g/mL) for 2 hours at room temperature. After they were washed, the samples were incubated with horseradish peroxidase-conjugated goat anti-rabbit antibody (Dako) and developed with the use of 3,3Ј,5,5Ј-tetramethybenzidine (BD Biosciences, Franklin Lakes, NJ). The absorbance was measured with a microplate reader (VersaMax; Molecular Devices, Sunnyvale, CA).
in RPMI 1640 with 1% fetal calf serum and incubated with peripheral blood mononuclear cells (PBMCs) (2.5ϫ10 5 cells per well). For blocking experiments, PBMCs were preincubated with p216c (60 g/mL) for 30 minutes. Levels of interleukin (IL)-8 in supernatant were assessed after 24 hours of incubation by enzymelinked immunosorbent assay.
Statistical Analysis
Quantitative data are expressed as meanϮSEM. The nonparametric Mann-Whitney U test was used for 2-group comparisons, and the Kruskal-Wallis test was used for multigroup comparisons. Differences between groups were considered significant at PϽ0.05.
Results

Identification of ApoBDS-1 in ApoB100
To determine whether ApoB100-derived peptides have bioactivity to stimulate monocyte/macrophages, THP-1 cells were treated with 302 synthetic peptide of ApoB100. IL-8 secretion was used to reveal cell activation. At 25 g/mL, we observed that at least 6 native peptides-P208, P211, P218, P243, P292, and P216 (Table) -triggered IL-8 production ( Figure 1A ).
To confirm these initial observations, the activity of these peptides was examined in THP-1 cells. Among them, P216 was the most effective peptide, eliciting dosedependent production of IL-8 ( Figure 1B) , and it was termed ApoBDS-1.
During LDL oxidation, a common modification is the addition of malondialdehyde adducts to the lysyl residues of ApoB100. 4 Notably, the modification of ApoBDS-1 with malondialdehyde quenched its bioactivity ( Figure 1C ).
In addition to THP-1 cells ( Figure 1B ), primary cells from blood were also examined. Human PBMCs (Figure 2A ) and monocyte-derived macrophages ( Figure 2B ) were more sensitive to ApoBDS-1 than THP-1 cells, as evidenced by a 10-fold increase in IL-8 production. Consistent with its effect on IL-8 production, ApoBDS-1 upregulated IL-8 mRNA levels in PBMCs ( Figure 2C ). Collectively, these results demonstrate that ApoBDS-1 is a distinct peptide of ApoB100 that has robust bioactivity, inducing IL-8 secretion by monocytes and macrophages.
Because lipopolysaccharide is a widespread contaminant of biochemical preparations and active at extremely low concentrations, we determined whether the effect of ApoBDS-1 was attributed to lipopolysaccharide contamination. Four independent batches of synthetic ApoBDS-1 were tested, showing consistent activity throughout this study, arguing against coincidental lipopolysaccharide contamination (data not shown). Furthermore, ApoBDS-1-induced IL-8 production was unaffected by the lipopolysaccharide inhibitor polymyxin B, which suppressed Ͼ90% of lipopolysaccharide-induced IL-8 levels ( Figure 2D ). In addition, IL-8 could not be induced by ApoBDS-1 in human embryonic kidney cells that were stably transfected with Toll-like receptor 4 ( Figure 2E ). These data demonstrate that activation by ApoBDS-1 is not caused by lipopolysaccharide contamination.
The Bioactivity of ApoBDS-1 Is Sequence Dependent
To gain insights into its sequence-activity relationship, ApoBDS-1 was truncated into 3 short fragments, each consisting of 10 amino acids (Table) . None of the truncated fragments induced IL-8 production in PBMCs (Figure 2G ). Furthermore, P215 and P217, the peptides flanking on either end of ApoBDS-1 in the sequence of ApoB100, were used as controls and failed to elicit IL-8 secretion ( Figure 2G ).
Effect of ApoBDS-1 on Induction of Proinflammatory Mediators
To examine the function of ApoBDS-1 in the proinflammatory response in greater detail, 10 additional chemokines and cytokines were measured by cytometric bead array in the supernatants of PBMCs that were incubated with ApoBDS-1 for 6 and 24 hours ( Figure 3 ). IL-6 ( Figure 3A ) was rapidly induced by ApoBDS-1 at 6 hours, followed by IL-8 and CCL2 (monocyte chemotactic protein-1) production at 24 hours ( Figure 3B ). There was no effect, however, on IL-1␤, tumor necrosis factor-␣, IL-12p70, interferon-␥, IL-10, CXCL10 (IP-10), or CXCL9 (MIG) ( Figure 3 ). These data suggest that ApoBDS-1 influences a subset of inflammatory mediators, including an unexpected downregulation of CCL5 release after 24 hours of treatment ( Figure 3B ).
ApoBDS-1 Increases Calcium Flux and MAPK Phosphorylation
Next we explored the signaling mechanisms implicated in the ApoBDS-1-induced cytokine and chemokine responses. Cal- cium signaling is critical for the activation of transcriptional regulatory pathways that underlie inflammatory and immune responses. 18 We observed that PBMCs responded to ApoBDS-1 by a rapid increase in Ca 2ϩ flux within 30 seconds ( Figure 4A and 4B) and subsequent slow decline over 240 seconds, with leveling off ( Figure 4B ). Importantly, ApoBDS-1-induced IL-8 production was completely abolished in the presence of the calcium chelator 1,2-bis(2-aminophenoxy) ethane-N,N,NЈ,NЈ-tetraacetic acid (BAPTA) ( Figure 4C ), indicating that Ca 2ϩ flux is an early but also a critical signaling mechanism in the course of ApoBDS-1-triggered IL-8 production.
Because Ca 2ϩ signaling is implicated in the modulation of MAPK pathways, we examined the response of MAPKs in THP-1 cells treated with ApoBDS-1. Activated ERK1/2 and JNK were evident 10 minutes and 60 minutes after ApoBDS-1 stimulation ( Figure 4D ). p38, however, responded in a distinct manner characterized by gradually activating over time and peaking at 60 minutes ( Figure 4D ).
Next MAPK inhibitors were used to determine the role of MAPKs in ApoBDS-1-induced IL-8 production. Pretreatment of PBMCs with the ERK1/2 specific inhibitor PD98089 or the JNK specific inhibitor SP600125 did not affect ApoBDS-1-induced IL-8 mRNA expression or IL-8 release ( Figure 4E and 4F) . In contrast, blockade of p38 with SB203580 resulted in Ͼ90% reduction of IL-8 mRNA and protein ( Figure 4E and 4F) . These data show that p38-MAPK is the critical signaling mechanism underlying ApoBDS-1induced IL-8 production.
ApoBDS-1 Elicits Inflammatory Responses in Atherosclerotic Lesions
To determine the relevance of ApoBDS-1 to inflammation in atherosclerosis, we established an ex vivo atherosclerotic model using fresh atherosclerotic plaque tissue from human carotid arteries. Eight plaques were stimulated with 2 concentrations of ApoBDS-1, and levels of inflammatory mediators were measured 24 hours later.
The ex vivo cultured plaques released high levels of IL-8, IL-6, and CCL5 in an unstimulated condition ( Figure 5A ). Notably, ApoBDS-1 increased the production of IL-8 and IL-6 but not CCL5 ( Figure 5A ), consistent with the responses of in vitro treated PBMCs (Figure 3 ).
Furthermore, ApoBDS-1 triggered a dose-dependent production of the proinflammatory prostaglandin E 2 (PGE2) ( Figure 5A ), concomitant with a significant upregulation of microsomal prostaglandin E 2 synthase (mPGES-1) mRNA ( Figure 5B ) and IL-8 in plaques ( Figure 5B ). However, expressions of cyclooxygenase-1, cyclooxygenase-2, or the PGE2 receptors EP2, EP3, or EP4 were not greatly altered ( Figure 5B ).
ApoBDS-1-Positive Peptides Are Present in Carotid Atherosclerotic Plaques
To further establish the relevance of ApoBDS-1 to atherosclerosis, we verified whether ApoBDS-1 exists in atherosclerotic lesions. For this purpose, we made an antibody that shows definitive specificity to ApoBDS-1 ( Figure I artery. The specificity of the observed ApoBDS-1 signals was confirmed by competitive blocking with the use of ApoBDS-1 peptide ( Figure 6B and 6C ). Of note, the intracellular ApoBDS-1 signal was predominantly colocalized with CD68 positive macrophages ( Figure 6D ), occasionally with smooth muscle cells ( Figure 6E ), but was not found in endothelial cells ( Figure 6F ). These results show that ApoBDS-1-containing peptides are present in atherosclerotic lesions.
Evidence of Low-Molecular-Weight ApoBDS-1-Positive Peptides in Atherosclerotic Plaques
To further characterize the endogenous ApoBDS-1 peptides, plaque homogenates were analyzed. Western blot analysis of denatured plaque proteins showed that ApoBDS-1 peptides are present in different molecular weights in vivo ( Figure  7A ). Two small ApoBDS-1 peptide fragments (ie, Ϸ40 and 15 kDa in molecular weight) were noted in all tested plaques.
Separation of plaque homogenates in nonreducing condition by size-exclusion chromatography followed by detection of ApoBDS-1 with the use of the anti-ApoBDS-1 antibody confirmed that a major portion of ApoBDS-1 peptides exists in vivo in molecular weights ranging between 10 and 42 kDa ( Figure 7B ).
Low-Molecular-Weight Endogenous ApoBDS-1-Positive Fractions Contain ApoBDS-1-Specific Capacity to Trigger IL-8 Production
Finally, we investigated whether the peptides isolated from plaque carry the bioactivity of ApoBDS-1. PBMCs were incubated with 7 ApoBDS-1-positive chromatographic fractions corresponding to the calibrated molecular weight 10 to 42 kDa. In accordance, all 7 fractions significantly enhanced IL-8 production ( Figure III in the online-only Data Supplement). To define the specific ApoBDS-1 activity in these peptide fractions, the response of IL-8 was determined in the presence of excess peptide P216c, a truncated ApoBDS-1 that lacks biological activity ( Figure 2G and Figure IV in the online-only Data Supplement). All 7 fractions were partially blocked to various degrees by P216c; 1 fraction collected at 49 minutes was overtly affected, as indicated by a 63% reduction in IL-8 response in the presence of p216c ( Figure 7C ). Altogether, these results imply that peptides with ApoBDS-1 activity can be found in atherosclerotic plaque.
Discussion
Inflammatory properties of modified LDL contribute to the development of atherosclerosis. 19 -21 In this study, we investigated the relevance of peptides derived from the protein part of LDL, ApoB100, to the inflammatory response in atherosclerosis.
By screening a peptide library of human ApoB100, we have identified a previously unrecognized native peptide fragment that exhibits distinctive activity triggering inflammatory responses in human monocytes/macrophages and atherosclerotic plaques ex vivo. Importantly, the peptides with specific ApoBDS-1 activity are present in atherosclerosis. Given its capacity to induce innate immune responses, we named the peptide ApoBDS-1, signifying the first identified ApoB100-derived danger-associated signal.
ApoBDS-1 has several important properties that contribute to inflammation in atherosclerosis. The molecular mechanism that evokes infiltration of leukocytes into the arterial wall is crucial for the development of atherosclerosis. Our results indicate that ApoBDS-1 induces the production of a subset of chemokines that are implicated in the recruitment of monocytes and T lymphocytes in chronic inflammatory diseases, including atherosclerosis. Furthermore, ApoBDS-1 is a potent stimulus of mPGES-1 pathway, resulting in augmentation of PGE2 biosynthesis in the atherosclerotic lesion. Because PGE2 can aggravate the inflammatory response and evoke progression of atherosclerosis at least in part by enhancement of vascular oxidative stress, by impairing endothelial function, and by modulation of platelet aggregation and arterial thrombosis, [22] [23] [24] [25] it is likely that ApoBDS-1 has an important impact on the pathogenic processes of atherosclerosis. In support of this concept, we have shown that ApoBDS-1 also induces IL-6, another pleiotropic cytokine with detrimental effects on atherosclerotic plaque development. 26, 27 These bioactivities, as demonstrated in our ex vivo model of atherosclerosis, link ApoBDS-1 to its pathogenesis. Whereas ApoBDS-1 induces production of IL-6, IL-8, and PGE2, it does not trigger expression of potent proinflammatory cytokines, such as IL-1␤ and tumor necrosis factor-␣. This points to a role of ApoBDS-1 in a scenario of low-grade chronic inflammation. Of note, the in vitro cellular responses suggest that ApoBDS-1 directly activates monocytes and macrophages but not T lymphocytes. The molecular mechanism responsible for the cellular specificity, however, needs further investigation.
These observations postulate a new paradigm for the role of LDL in atherosclerosis. ApoBDS-1, once it is exposed or released from ApoB100 of LDL, may act alone or in concert with oxidized phospholipids as primary danger molecules, generating signals that recruit inflammatory cells into the vessel wall and precipitate chronic inflammation in the atherosclerotic lesion.
The present study has also shed light on signaling pathways involved in the peptide-induced activated inflammatory responses. Our data suggest that there are 2 related signaling modes that cooperate during ApoBDS-1-induced activation of monocytes/macrophages. Initially, rapid intracellular Ca 2ϩ mobilization occurs on peptide stimulation and appears to be indispensable for the induction of IL-8. Subsequently, the peptide activates MAPKs, including ERK, JNK, and p38. Of the MAPKs, p38-MAPK acts as the principal signaling mechanism of the induced IL-8 expression, based on the effects of the selective p38 inhibitor. Moreover, ERK1/2 activation seems to be involved in the regulation of IL-8 secretion. These findings suggest that 2 signaling pathways, involving Ca 2ϩ and MAPK, coordinate to regulate IL-8 production in monocytes/macrophages. Activation of the p38-MAPK pathway by ApoBDS-1 implicates rather broad bioactivities for this peptide in atherosclerosis. p38-MAPK has been shown to induce the inflammatory mediators tumor necrosis factor-␣, PGE2, and IL-6 and also to regulate many cellular processes, including proliferation, apoptosis, and migration. 22, 28 This notion is further supported by the increased response of IL-6, IL-8, and microsomal prostaglandin E 2 synthase-1/ PGE2 in plaques to the peptide stimulation. Because p38-MAPK is known as the canonical signaling pathway mediating inflammatory responses induced by oxidized LDL and oxidized phospholipids, 29, 30 these studies together with the present study lead to the perception that activation of p38-MAPK is likely the central signaling mechanism responsible for bioactivities of LDL in atherosclerosis. The exact transmembrane signaling pathways through which ApoBDS-1 activates Ca 2ϩ and MAPKs are unknown, and whether there is a specific receptor that interacts with ApoBDS-1 needs to be determined.
Several lines of evidence demonstrate the involvement of ApoB100-derived peptides in atherosclerosis. Clinical studies have identified antibodies that recognize modified as well as native ApoB100 peptides in association with disease progression. In fact, some of these peptides effected immune protection in experimental models of atherosclerosis. [31] [32] [33] These findings show that the ApoB100 peptide library can be used to recapitulate immune responses in atherosclerosis.
Three lines of evidence in this study support the concept that bioactive ApoBDS-1 is present in atherosclerosis. Im- munostaining with the use of a specific antibody shows that abundant ApoBDS-1-positive signals are present in human carotid plaques. Western blot and size-exclusion chromatography analysis of plaque homogenates consistently demonstrate that ApoBDS-1-containing fragments exist in large-and also in small-molecular-weight fractions in atherosclerotic plaques. Most importantly, some of these small ApoBDS-1-positive peptide fractions carry specific ApoBDS-1 activity (ie, the capacity to induce IL-8 secretion by PBMCs). However, further studies are still needed to elucidate the sequences and the structures of these bioactive ApoBDS-1 fractions. The process of generation of ApoBDS-1 in vivo is still poorly understood. According to the structural analysis of ApoB100 protein, 34 ApoBDS-1 is in part embedded in the surface-exposed proline-rich domain 2 of ApoB100 and should therefore be susceptible to proteolytic cleavage. Indeed, trypsinization of ApoB100 results in 4 peptides from the proline-rich domain 2, 1 of which is nearly identical in sequence to ApoBDS-1. 35 Protease activity in atherosclerotic lesions is high, and abundant lysosomal proteases exist in the macrophage-rich regions. 36 -38 Not surprisingly, in atherosclerotic lesions, ApoB100 can be processed by proteases and reactive oxygen species into various-sized peptide fragments in plaques, arguing for the fragmentation of ApoB100 as an inevitable process. 39, 40 We observed that abundant ApoBDS-1 staining is colocalized with lesional macrophages or in the extracellular space in atherosclerotic lesions. However, whether the featured localization of ApoBDS-1 is implicated in the process of ApoB100 degradation and generation of the bioactive peptides needs to be clarified.
In conclusion, our study has identified a novel native ApoB100-derived peptide that activates monocytes/macrophages to secrete cytokines and chemokines. These findings shed light on the function of LDL as danger signal 40 in atherosclerosis. Figure 7 . Detection of bioactive apolipoprotein B100 danger-associated signal 1 (ApoBDS-1) peptides generated in vivo. In vivo generated ApoBDS-1 peptides were identified by Western blot (A) or enzyme-linked immunosorbent assay of the chromatographic fractions (B) from plaque homogenates as described in Methods (nϭ3 different plaques). Left braces indicate the different ranges of molecular weight; black arrow points to control ApoBDS-1 band; dotted lines show the different ranges of molecular weight. C, Interleukin (IL)-8 production in response to ApoBDS-1-positive chromatographic fractions with low molecular weight ranging from 10 to 42 kDa was determined as described in Methods. Peripheral blood mononuclear cells (2ϫ10 5 ) were stimulated with the peptide fractions of plaques in the presence or absence of the competitive inhibitor peptide P216c (5-fold molar ratio 
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CLINICAL PERSPECTIVE
Accumulated low-density lipoprotein particles in arterial wall are the primary cause of atherosclerosis by triggering chronic vascular inflammation, characterized by local activation of cellular inflammatory responses including lesional macrophages. The molecular identities of low-density lipoprotein-derived inflammatory components have been poorly defined. Apolipoprotein B100 (ApoB100) is the only unchangeable protein constituent of the low-density lipoprotein particle. Both clinical and preclinical studies suggest that ApoB100 protein fragments are implicated in modulation of immune responses in the process of disease development, implying that ApoB100 is not a bystander to the inflammation of atherosclerosis.
In the present study, by screening a peptide library of human ApoB100, we have identified a previously unrecognized native peptide fragment that exhibits distinctive activity triggering inflammatory responses of human monocytes/macrophages and atherosclerotic plaques ex vivo. Given its capacity to induce innate immune responses, we named the peptide ApoB100 danger-associated signal 1, signifying the first identified ApoB100 -derived danger-associated signal. Importantly, the peptides with specific ApoB100 danger-associated signal 1 activity are present in atherosclerosis. These findings shed light on the pathobiological role of low-density lipoprotein in atherosclerosis.
